Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Mahavir Laboratories Pvt Ltd

    Mahavir Laboratories Pvt Ltd is engaged in production of pharmaceutical API?s and finished formulations. They are an IS0 9001 : 2000 registered company and their production faci

  • No Image
    Makcur Laboratories Ltd

    Makcur Laboratories Ltd was incorporated in April 1996, is located near Dehgam, District, Gandhinagar, Gujarat. Mr. Dhirajbhai Laljibhai Patel is the promoter and Managing Direc